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Over the past several years, there has
been an evolving transformation in our
understanding of the role of the micro-
vasculature in normal tissue and tumor
responses to radiation and drugs. The
classical model of tumor radiotherapy
defines depletion of tumor stem cells and
undifferentiated progenitor clonogens as
obligatory for the curative effect of 
radiation, while damage to tumor micro-
environmental elements is believed to
provide modulating, though not manda-
tory, signals. Recent genetic and phar-
macologic studies have, however,
revealed that crosstalk between tumor
cells and the host-derived tumor
microvascular network, both damaged
by radiation, constitutes a generic ele-
ment of the pathogenesis of radiation-
induced tissue damage. The studies by
Moeller et al. (2004, 2005) provide the
first mechanistic insight into tumor cell-
microvascular interactions that occur
during the course of fractionated radio-
therapy. Radiation treatment of human
cancer is commonly delivered by frac-
tionated schemes, consisting of a daily
small dose, repeated until a potentially
curative tumor-specific dose has accu-
mulated. Fractionated radiation has been
favored because it affords protection to
normal tissues relative to tumors, as nor-
mal tissue stem cells appear to be more
proficient in radiation damage repair 
during the interfractional intervals than
tumor clonogens.
Prior work of Moeller et al. (2004)
provided strong evidence that bursts of
reactive oxygen species (ROS), generat-
ed by waves of hypoxia/reoxygenation
occurring after each radiation exposure,
lead to induction of hypoxia-inducible
factor-1 (HIF-1) activity. The HIF-1 tran-
scription factor regulates adaptive
responses to changes in tissue oxygena-
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Recent research has shed new light on the critical role of tissue microvasculature in regulating the tumor response to radi-
ation and drugs. In this issue of Cancer Cell, Moeller et al. (2005) demonstrate that HIF-1 activation during the course of
fractionated radiotherapy initiates pleiotropic adaptive responses in both tumor cells and the microvascular network,
radiosensitizing tumor cells but concomitantly conferring tumor radioresistance due to protection of the microvascular
endothelium. HIF-1 thus serves as a legitimate target for differential modulation of tissue response to radiation.
Figure 1. Models of microvascular endothelial engagement in tumor response to single-dose or fractionated radiotherapy
Endothelial damage appears to be induced by both the high treatment doses (>810 Gy) of single-dose radiotherapy (A) and the low-dose
(1.83 Gy) exposures of fractionated radiotherapy (B). The resulting microvascular dysfunction confers conversion of sublethal radiation lesions in
tumor cells into lethal lesions via an as yet unknown mechanism.
Endothelial apoptosis and microvascular dysfunction contribute significantly to tumor cell lethality and tumor cure by the single-dose approach.
Radiation induces translocation of endothelial cell ASMase into glycosphingolipid- and cholesterol-enriched plasma membrane rafts, where it
hydrolyses sphingomyelin (SM) to generate the proapoptotic second messenger ceramide, initiating transmembrane signaling of apoptosis.
Inhibition of this process by ASMase depletion or by proangiogenic growth factors markedly attenuates the lethal response of tumor cells to this
mode of radiotherapy.
In contrast, the endothelial cell damage induced by the low-dose exposures of fractionated radiotherapy does not enhance tumor cell death
effectively, as the death signaling pathway in endothelium is repressed by concomitant activation of tumor cell HIF-1. ROS generated by waves
of hypoxia/reoxygenation occurring after each radiation exposure lead to translation of HIF-1 mRNA transcripts stored in specialized cytosolic
stress granules of hypoxic tumor cells. This adaptive response generates VEGF and other proangiogenic factors that attenuate radiation-induced
apoptosis in endothelial cells. Genetic inhibition of the HIF-1 response leads to extensive endothelial apoptosis, microvascular dysfunction,
enhanced tumor cell death, and tumor growth delay. The mechanism of endothelial damage in this response remains unknown, and a possible
involvement of the ASMase pathway has not as yet been assessed. This observation indicates a potential for pharmacologic targeting of HIF-1 to
improve the outcome of fractionated radiotherapy via engagement of the endothelial apoptosis component.
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tion, engaging more than 60 target
genes, all driven by promoters that con-
tain a hypoxia response element (HRE)
(Semenza, 2003). Remarkably, HIF-1
upregulation during fractionated radio-
therapy does not result from gene tran-
scription secondary to waves of hypoxia.
Rather, the reoxygenation-induced ROS
appear to initiate translation of pre-
formed HIF-1 mRNA transcripts, stored
in specialized cytosolic stress granules.
Sequestration of HIF-1 transcripts in
these granules is preconditioned by
chronic tumor hypoxia, which develops in
many tumors when neoangiogenesis
lags behind the expansion of the tumor
cell compartment. The postradiation
translation of HIF-1 results in upregula-
tion of VEGF and other proangiogenic
factors that protect tumor endothelium,
conferring radioresistance. Moeller et al.
(2005) now report that in contradistinc-
tion to endothelial cell protection, radia-
tion-induced HIF-1 also regulates gene
products that enhance tumor cell
radiosensitivity through increased apo-
ptotic potential, proliferation rates, and
ATP metabolism. However, p53 is
required for HIF-1-mediated tumor cell
apoptosis. Since more than half of tumor
phenotypes are p53-mutated, the vascu-
lar-mediated radioresistance appears
dominant in affecting overall tumor sensi-
tivity to fractionated irradiation. In this
context, genetic or pharmacologic HIF-1
inactivation resulted in dramatic regres-
sion of tumor microvasculature, appar-
ently secondary to deprivation of
HIF-1-activated factors, and significant
enhancement of tumor growth delay,
regardless of whether HIF-1 inhibition
occurred before or after completion of
radiotherapy.
These unique observations raise
further questions regarding the mech-
anism of endothelial engagement in the
response to fractionated radiotherapy.
Clearly, an endothelial damage compo-
nent is required for tumor microvascular
regression, since HIF-1 deprivation alone
does not elicit endothelial damage or
tumor response in control unirradiated
tumors. The kinetics of the response to
HIF-1 deprivation suggest that irradiated
endothelium harbors pro-death signals,
quenched by HIF-1-induced growth 
factors and cytokines. These pro-death
signals appear to be sustained in
endothelium, since genetic inactivation of
HIF-1 after completion of radiotherapy
still conferred endothelial cell death and
enhanced tumor growth delay. Moeller et
al. suggest that HIF-1 may protect the
endothelium via VEGF and/or bFGF.
However, other tumor models in which
endothelial survival is conferred by adja-
cent tumor cell signals have shown that
VEGF is not sufficient for maintaining
endothelium. Chin et al. (1999) reported
that expression of H-RasV12G in a 
doxycycline-inducible H-RasV12G mouse
melanoma model is required for survival
of host-derived tumor endothelium.
Withdrawal of doxycycline and H-RasV12G
downregulation resulted in marked apop-
tosis of tumor microvascular endotheli-
um, which could not be rescued by
retrovirally enforced VEGF expression.
The impact of endothelial protection on
the outcome of clinical fractionated radio-
therapy protocols thus requires further
clarification, as it appears to introduce an
element of radioresistance. While the
experimental protocol used by Moeller et
al. consisted of three fractions of 3 Gy
delivered over 36 hr, curative fractionated
radiotherapy usually involves 25–40 frac-
tions of 1.8–2 Gy each, delivered over
several weeks. Hence, it remains to be
established whether HIF-1 induction by
waves of reoxygenation-induced ROS
can be sustained over such a prolonged
series of repeated stimulations, and
whether the endothelium might develop
resistance to HIF-1-mediated signals
when repeated with such frequency.
The paradigm of endothelial involve-
ment in fractionated radiotherapy,
described by Moeller et al., is evidently
distinct from the mechanism of endothe-
lial involvement in curative single-dose
radiation (Figure 1). The clinical use 
of single-dose radiotherapy has increased
recently due to the emergence of image-
guided, high-precision targeting of human
tumors. This approach maximally avoids
surrounding normal tissues, enabling
application of large tumoricidal radiation
doses with minimal normal tissue toxici-
ty. Studies by Garcia-Barros et al. (2003)
revealed that exposure of mouse
MCA129 fibrosarcoma and B16
melanoma to single doses of 15–20 Gy
is followed by a rapid wave of endothelial
apoptosis at 1–6 hr as the earliest
anatomical evidence of tissue damage.
Tumor cells appeared intact for 2–3 days,
subsequently succumbing to treatment
and leading to different rates of local
tumor cure or tumor growth delay,
depending on dose and tumor type. The
mechanism of endothelial apoptosis in
this response has been extensively
explored (Kolesnick and Fuks, 2003) and
shown to be mediated via the acid 
sphingomyelinase (ASMase) pathway.
ASMase hydrolyzes sphingomyelin to
generate the proapoptotic second mes-
senger ceramide. Radiation induces
rapid translocation of a secretory form of
ASMase from cytosol into glycosphin-
golipid- and cholesterol-enriched rafts in
the outer leaflet of the plasma mem-
brane (Gulbins and Kolesnick, 2003),
where ceramide is rapidly generated,
coordinating transmembrane signaling of
apoptosis. Endothelial cells are 20-fold
enriched in secretory ASMase compared
with any other cell in the body, and 
are particularly sensitive to radiation-
induced apoptosis in vitro and in vivo via
the ASMase pathway.
The studies by Garcia-Barros et al.
(2003) showed that the early-phase
microvascular endothelial apoptosis is
mandatory for tumor cure, as MCA129
fibrosarcoma and B16 melanoma grown
in apoptosis-resistant asmase−/− or Bax−/−
mice were completely resistant to 15–20
Gy single-dose irradiation. These obser-
vations indicated that radiation-induced
lesions in tumor cells were by themselves
not lethal, and that their conversion to
lethal damage is tightly coupled to the
endothelial apoptotic response. The
mechanism of the endothelial-tumor link-
age is still unknown. It might involve leak-
age of a circulating factor, a bystander
effect secondary to endothelial damage,
or transient local ischemia/reperfusion
produced by the acute microvascular
dysfunction and its rapid reversal, per-
haps by recruitment of circulating mar-
row-derived endothelial progenitor cells
(Garcia-Barros et al., 2003). Of great
interest are preliminary observations that
human tumor specimens irradiated ex
vivo within 15 min of surgical resection
show the same rapid wave of endothelial
apoptosis and dose-response profile for
apoptosis as in the animal studies,
except for grade IV glioblastoma, which
exhibits apoptosis resistance (Fuks 
and Kolesnick, unpublished data). The
endothelial responses in mouse and
human tumor specimens both display an
apparent threshold at 8–10 Gy and a
maximal response at 20–25 Gy. The
endothelial-stem cell linked mechanism
would, therefore, not be activated by frac-
tionated radiation schemes using <8
Gy/fraction, as employed by Moeller et al.
This endothelial-stem cell linkage mech-
anism was also shown to mediate normal
tissue damage after single-dose expo-
sure of the intestines and lung (Kolesnick
P R E V I E W S
CANCER CELL : AUGUST 2005 91
and Fuks, 2003; Paris et al., 2001), sug-
gesting that this represents a generic
response mechanism for mammalian tis-
sue damage by large single-dose irradia-
tion. The possibility that a similar
crosstalk between microvasculature and
tumor clonogens occurs during fraction-
ated radiotherapy when the HIF-1-medi-
ated endothelial protection is removed,
such as reported by Moeller et al., repre-
sents a testable hypothesis.
In principle, the studies of Moeller et
al. support the notion that fractionated
radiotherapy, like single-dose radiation,
engages a vascular component of the
tumor response. In the case of fractionat-
ed radiotherapy, however, this response
is largely attenuated by adaptive signals
generated by HIF-1 activation. Hence,
Moeller et al. suggest that HIF-1 may
represent a valid target for radiosensiti-
zation via derepression of endothelial
cell death. However, they caution that
HIF-1 inactivation, if it is to be therapeuti-
cally efficacious, should be scheduled to
optimize tumor cell radiosensitization. In
contrast, the endothelial death signal
produced by large-dose exposure
(>8–10 Gy) may precede or be of suffi-
cient magnitude to overcome HIF-1 anti-
death protection. These provocative
studies should open up new avenues for
basic research into mechanisms of
endothelial cell damage and the role of
the microvascular response in therapy,
potentially providing new pharmacologic
targets for improving radiation and other
anticancer treatments.
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Hereditary tumor syndromes have
given numerous insights into cancer biol-
ogy. Often it is straightforward to see a
link between the genetic defect and
tumor predisposition. This is the case if
the gene product impinges on pathways
involved in cell proliferation or cell death.
In other examples, maintenance of the
genome is compromised, so that the like-
lihood of developing mutations that lead
to an increase in proliferation or death is
increased. But the link between the
genetic defect and tumor predisposition
is not always clear. Arguably, these
cases are most likely to lead to truly
novel insights into tumor development. A
paper from Bill Kaelin’s group in this
issue of Cancer Cell suggests that
apparently unlinked genes implicated in
paraganglioma act in a single common
pathway (Lee et al., 2005). The authors
provide evidence that all the genetic
defects act by decreasing the likelihood
of apoptosis of neural crest cells at the
time during development when levels of
nerve growth factor (NGF) become limit-
ing. The study gives particular insight
into the interesting issue of how muta-
tions affecting succinate dehydrogenase
components could be tumorigenic.
Paragangliomas are tumors of the
autonomic nervous system. Non-
chromaffin paragangliomas are rare, are
described as “chemodectomas,” and are
located in the head and neck. Chromaffin
paragangliomas are much commoner,
have endocrine activity, and are referred
to as “pheochromocytomas.” These are
usually located in the adrenal medulla
but sometimes occur in the pre- and par-
avertebral thoracoabdominal regions.
Familial paraganglioma syndromes can
A common pathway for genetic events leading to
pheochromocytoma
Mutations in VHL, RET, NF1, SDHB, SDHC, and SDHD can give rise to pheochromocytoma/paraganglioma.These different
genetic lesions may all act by decreasing the activity of a 2-oxoglutarate-dependent oxygenase, SM-20/EglN3/PHD3,
resulting in reduced apoptosis of neural crest cells during development.
Figure 1. As NGF levels become limiting dur-
ing development, mutations affecting NF1,
RET, VHL, and SDH subunits all decrease
apoptosis mediated by SM-20/EglN3/PHD3.
Adapted from Lee et al. (2005) to show inter-
actions with HIF.
